(HealthDay News) — For adults with migraine, atogepant 60mg once daily was superior to placebo for efficacy and functional measures of treatment across 3 trials, according to research published online ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback